Skip to Content

Newsroom

Back

SOLTI presence at SABCS 2018

SOLTI presence at SABCS 2018

26 Nov 2018

San Antonio Breast Cancer Symposium will take place at Texas (USA) from December 4th to 8th.

Please find below all the information about the studies led by SOLTI or with SOLTI's participation that will present results at the congress:  

  
Wednesday, December 5th

POSITIVE: A study evaluating Pregnancy, disease outcome and safety of interrupting endocrine therapy for premenopausal women with endocrine responsIVE breast cancer who desire pregnancy (IBCSG 48-14/BIG 8-13)
Pagani O, Partridge AH, Peccatori F, Azim HA, Colleoni M, Saura C, Kroep JR, Warner E, Gombos A, Sætersdal AB, Ruggeri M, Gelber RD, Sun Z. 

OT1-01-06, Endocrine Therapy, De 17:00h a 19:00h

Thursday, December 6th

SOLTI-1303 PATRICIA phase II trial (STAGE 1) -- Palbociclib and trastuzumab in postmenopausal patients with HER2-positive metastatic breast cancer
Ciruelos E, Villagrasa P, Paré L, Oliveira M, Pernas S, Cortés J, Soberino J, Adamo B, Vazquez S, Martínez N, Perelló A, Bermejo B, Martínez E, Garau I, Melé M, Morales S, Galván P, Pascual T, Canes J, Nuciforo P, Gonzalez X, Prat A

PD3-03, Next Steps in HER2 Targeted Therapy, De 7:00h a 9:00h

Tumor inflammation signature (TIS), intrinsic subtypes and chemo-endocrine score (CES) in metastatic triple-negative breast cancer (mTNBC): A SOLTI biomarker program study
Pascual T, Pernaut C, Tolosa P, Galvan P, Bárcena C, Vidal M, Manso L, Adamo B, Dueñas M, Muñoz M, Chic N, Gonzalez-Farre B, Villagrasa P, Ciruelos E, Prat A

P2-08-17, Prognostic and Predictive Factors: Other, De 7:00h a 9:00h

Exploratory biomarker analyses of FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (TNBC)
Wongchenko MJ, Oliveira M, Saura C, Nuciforo P, Calvo I, Andersen J, Passos Coelho JL, Gil Gil M, Bermejo B, Patt DA, Ciruelos E, Singel SM, Maslyar DJ, Xu N, de la Peña L, Baselga J, Gendreau S, Isakoff SJ

P2-08-19, Prognostic and Predictive Factors: Other, De 7:00h a 9:00h

SOLTI samples have been used in this study:

Standardized nCounter-based determination of estrogen receptor (ER), progesterone receptor (PR) and HER2 receptor status in breast cancer
Pascual T, Tsai YS, Martín M, Lluch A, Cortes J, Llombart A, Conte P, Guarneri V, Rimawi MF, Alba E, Ruiz-Borrego M, Rojo F, de la Haba J, Schiff R, Adamo B, Vidal M, Paré L, Chic N, Muñoz M, Galvan P, Gonzalez-Farre B, Brauer HA, Sullivan A, Nuciforo P, Parker JS, Prat A 

P2-08-06, Prognostic and Predictive Factors: Other, De 7:00h a 9:00h

Friday, December 7th

Early modulation of circulating microRNAs levels in HER2 positive breast cancer patients during neoadjuvant treatment
Di Cosimo S, Appierto V, Pizzamiglio S, Baselga J, Piccart M, Huober J, Izquierdo M, de la Pena L, Hilbers F, de Azambuja E, Untch M, Pusztai L, Pritchard KI, Nuciforo P, Salomon AV, Symmans FW, Apolone G, de Braud F, Verderio P, Daidone MG

P4-01-03, Detection/Diagnosis: Circulating BioMarkers & ctDNA , De 7:00h a 9:00h

Estrogen levels in premenopausal patients (pts) with hormone-receptor positive (HR+) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy final analysis
Bellet M, Gray K, Francis P, Láng I, Ciruelos E, Lluch A, Ángel Climent M, Catalán G, Avella A, Bohn U, González-Martin A, Zaman K, Ferrer R, Azaro A, Rajasekaran A, De la Peña L, Fleming G, Regan MM

P4-14-01, Treatment: Adjuvant Endocrine Therapy, De 7:00h a 9:00h

CORALLEEN: A phase 2 clinical trial of chemotherapy or letrozole plus ribociclib as neoadjuvant treatment for postmenopausal patients with luminal B/HER2-negative breast cancer
Gavila J, Saura C, Oliveira M, Ciruelos E, Gonzalez X, de la Peña L, Bermejo de las Heras B, Muñoz M, Fernandez P, Villagrasa P, Ortega V, Lopez R, Celiz P, Pascual T, Prat A

OT3-02-05, Poster Session OT3, De 17:00h a 19:00h

ALEXANDRA/IMpassion030: A phase III study of standard adjuvant chemotherapy with or without atezolizumab in early triple negative breast cancer
Ignatiadis M, McArthur H, Bailey A, Martinez J-L, De Azambuja E, Metzger O, Lai C, Ponde N, Goulioti T, Daly F, Bouhlel A, Balta V, Van Dooren V, Viale G, Maetens M, Dufrane C, Nguyen Duc A, Winer E, Gelber R, Piccart M

OT3-05-02, Targeted - CDK 4/6, De 17:00h a 19:00h

Anti-proliferative effect of oral metronomic vinorelbine (mVNB) in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): A randomized, three-arm, window-of-opportunity study
Prat A, Adamo B, Pascual T, Perez Fidalgo JA, Blanch S, Martínez N, Gomez Pardo P, Lopez Gonzalez A, Murillo Jaso L, Amillano K, Vidal M, Paré L, Canes J, Galvan P, Gonzalez Farre B, Ortega Cebrián V, Gonzalez X, Bellet Ezquerra M, Villagrasa P, Ciruelos E

P5-11-04, Prognostic and Predictive Factors: Predictive Biomarkers for Endocrine Therapies, De 17:00h a 19:00h

Overcoming barriers to achieve a successful breast cancer patient recruitment: Professionals' views
Casas A, Gonzàlez X, Capelán M, Morales J, Fabián M, Ciruelos E, Gabriele G

P5-13-05, Psychosocial, QOL, and Educational Aspects: Disparities and Barriers to Care, De 17:00h a 19:00h

Saturday, December 8th

Dynamics of tumor-infiltrating lymphocytes (TILs) during neoadjuvant dual HER2 blockade in HER2-positive (HER2+) breast cancer in the absence of chemotherapy
Griguolo G, Holgado E, Cortés J, Fasani R, Pascual T, Paré L, Bermejo B, Oliveira M, Morales S, Martinez N, Vidal M, Pernas S, Lopez R, Muñoz M, Galvan P, Garau I, Manso L, Alarcín J, Martínez E, Villagrasa P, LLombart-Cussac A, Prat A, Nuciforo P

P6-17-08, Treatment: HER2-Targeted Therapy, De 7:00h a 9:00h

Primary and secondary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)
Pernas S, Villagrasa P, Nuciforo PG, Vivancos A, Scaltriti M, Rodón J, Burgués O, Canes J, Dueñas M, Cecchi F, Vidal M, Lluch A, Perelló A, Llombart A, Dorca J, Montaño A, Oliveira M, Ribas G, Rapado I, Paré L, Prat A, Ciruelos E

P6-18-02, Treatment: Advanced Therapy - Targeted, De 7:00h a 9:00h

SOLTI samples have been used in this study:

Gene signatures and subtype changes during HER2 dual blockade in PAM50 HER2-enriched HER2-positive breast cancer
Brasó-Maristany F, Griguolo G, Llombart-Cussac A, Pascual T, Paré L, Bermejo B, Oliveira M, Morales S, Martinez N, Vidal M, Pernas S, Lopez R, Muñoz M, Galvan P, Garau I, Manso L, Alarcón J, Martínez E, Villagrasa P, Cortés J, Prat A

P6-17-07, Treatment: HER2-Targeted Therapy, De 7:00h a 9:00h


Press Dossier

Download the SOLTI Press Kit
Date: 18 May 2016
Download

Contacts

SOLTI Communication Area
X
Utilizamos cookies propias y de terceros para mejorar nuestros servicios mediante el análisis de sus hábitos de navegación. Puede cambiar la configuración u obtener más información aquí.